

WO 99/61590

- 41 -

What Is Claimed Is:

1. An article of manufacture comprising packaging material and a pharmaceutical composition contained within said packaging material, wherein said pharmaceutical composition is capable of modulating angiogenesis in a tissue associated with a disease condition, wherein said packaging material comprises a label which indicates that said pharmaceutical composition can be used for treating disease conditions by modulating angiogenesis, and wherein said pharmaceutical composition comprises a Src protein or an oligonucleotide having a nucleotide sequence capable of expressing said protein.
2. The article of manufacture of claim 1 wherein said Src protein is an active Src protein and said modulating potentiates angiogenesis.
3. The article of manufacture of claim 2 wherein said active Src protein is Src A.
4. The article of manufacture of claim 2 wherein said tissue has poor circulation.
5. The article of manufacture of claim 1 wherein said tyrosine kinase Src protein is an inactive Src protein and said modulating inhibits angiogenesis.
6. The article of manufacture of claim 5 wherein said inactive Src protein is Src 251 or Src K295M.
7. The article of manufacture of claim 5 wherein said tissue is inflamed and said condition is arthritis or rheumatoid arthritis.
8. The article of manufacture of claim 5 wherein said tissue is a solid tumor or solid tumor metastasis.
9. The article of manufacture of claim 8 wherein said administering is conducted in conjunction with chemotherapy.
10. The article of manufacture of claim 5 wherein said tissue is retinal tissue and said condition is retinopathy, diabetic retinopathy or macular degeneration.
11. The article of manufacture of claim 5 wherein said tissue is at the site of coronary angioplasty and said condition is restenosis.
12. The article of manufacture of claim 1 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

- 42 -

13. The article of manufacture of claim 1 wherein said administering comprises a single dose intravenously.

14. The article of manufacture of claim 1 wherein said pharmaceutical composition further comprises a liposome.

5 15. The article of manufacture of claim 1 wherein said pharmaceutical composition comprises a viral expression vector capable of expressing said nucleotide sequence.

10 16. The article of manufacture of claim 1 wherein said pharmaceutical composition comprises an non-viral expression vector capable of expressing said nucleotide sequence.

17. A method for modulating angiogenesis in a tissue associated with a disease condition comprising administering to said tissue a pharmaceutical composition comprising a Src protein or a nucleotide sequence capable of expressing said protein.

15 18. The method of claim 17 wherein said Src protein is an active Src protein and said modulating potentiates angiogenesis.

19. The method of claim 18 wherein said active Src protein is Src A.

20. The method of claim 18 wherein said tissue has poor circulation.

21. The method of claim 17 wherein said Src protein is an inactive Src protein and said modulating inhibits angiogenesis.

22. The method of claim 21 wherein said inactive Src protein is Src 251 or Src K295M.

23. The method of claim 21 wherein said tissue is inflamed and said condition is arthritis or rheumatoid arthritis.

25 24. The method of claim 21 wherein said tissue is a solid tumor or solid tumor metastasis.

25. The method of claim 24 wherein said administering is conducted in conjunction with chemotherapy.

30 26. The method of claim 21 wherein said tissue is retinal tissue and said condition is retinopathy, diabetic retinopathy or macular degeneration.

27. The method of claim 21 wherein said tissue is at the site of coronary angioplasty and said tissue is at risk for restenosis.

- 43 -

28. The method of claim 17 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

29. The method of claim 17 wherein said administering comprises a single dose intravenously.

5 30. The method of claim 17 wherein said pharmaceutical composition further comprises a liposome.

31. The method of claim 17 wherein said pharmaceutical composition comprises an retroviral expression vector capable of expressing said nucleotide sequence.

10 32. The method of claim 17 wherein said pharmaceutical composition comprises an non-viral expression vector capable of expressing said nucleotide sequence.

15 33. A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for a src protein, said src protein having any amino acid residue at codon 527 except for tyrosine, serine or threonine.

20 34. A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for a src protein and said src protein having any amino acid residue at codon 527 except tyrosine, serine or threonine.

25 35. A pharmaceutical composition for inhibiting angiogenesis in a target mammalian tissue comprising a viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for a src protein having no kinase activity.

30 36. A pharmaceutical composition for inhibiting angiogenesis in a target mammalian tissue comprising a non-viral gene transfer vector containing a nucleic acid and pharmaceutically acceptable carrier or excipient; said nucleic acid having a nucleic acid segment encoding for a src protein, said src protein having no kinase activity.

37. A pharmaceutical composition for stimulating angiogenesis in a target mammalian tissue comprising a therapeutic amount of a src protein in a

- 44 -

pharmaceutically acceptable carrier or excipient; said src protein having any amino acid residue at codon 527 except tyrosine, serine or threonine.

38. A pharmaceutical composition for inhibiting angiogenesis in a target mammalian tissue comprising a src protein in a pharmaceutically acceptable carrier or excipient; said src protein having no kinase activity.